Steve Runnels

Commercialization Partner CEO, Myosana Therapeutics

Steve Runnels

Commercialization Partner CEO, Myosana Therapeutics

Steve Runnels has more than 28 years of successful and proven international business management experience in the healthcare industry. He has held the position of president and CEO of several start-up biopharmaceutical companies, in the U.S. and Internationally. He was executive vice president and board member of publicly traded NeoTherapeutics, Inc. (NEOT: NASDAQ) and Vice President of Marketing and Business Development at Sigma-Aldrich, a Fortune 500 company. He has led drug discovery and in vitro diagnostic product development activities in the therapeutic areas of central nervous system, oncology, clinical cytogenetics, assisted reproductive technologies, immunohematology and diseases of bone and cartilage. Mr. Runnels is an entrepreneur-in-residence at the University of Washington, OHSU and Fred Hutch Cancer Research Center. He recently held the position as CEO of ProteoTech, Inc., a private, clinical stage company focused on the development of therapeutics for Parkinson’s disease, Alzheimer’s disease and AL amyloidosis. He is a senior industry advisor for the National Institutes of Health Commercialization Program (NIH-CAP) managed by the Los Angeles Regional Technology Association (LARTA). He holds a B.S. in cell biology and certification from the American Society of Clinical Pathology as a specialist in immunohematology.

Commercialization Partners